Efficacy and safety of asciminib, a specific allosteric BCR-ABL1 inhibitor targeting the myristoyl-binding site, in patients with chronic myeloid leukemia (CML) carrying the T315I mutation Meeting Abstract


Authors: Deininger, M. W.; Réa, D.; Lang, F.; Kim, D. W.; Cortes, J. E.; Hughes, T. P.; Minami, H.; Breccia, M.; DeAngelo, D. J.; Hochhaus, A.; Talpaz, M.; Goh, Y. T.; Le Coutre, P. D.; Etienne, G.; Sondhi, M.; Mishra, K.; Aimone, P.; Mauro, M. J.
Abstract Title: Efficacy and safety of asciminib, a specific allosteric BCR-ABL1 inhibitor targeting the myristoyl-binding site, in patients with chronic myeloid leukemia (CML) carrying the T315I mutation
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: clinical trial; cml; tyrosine kinase inhibitor; chronic; myelogenous leukemia; asciminib
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S289
End Page: S290
Language: English
ACCESSION: WOS:000483480700271
DOI: 10.1016/j.clml.2019.07.234
PROVIDER: wos
Notes: Meeting Abstract: CML-045 -- Source: Wos
Altmetric Score
MSK Authors
  1. Michael John Mauro
    134 Mauro